Canagliflozin's Comparative Impact on Heart Failure Hospitalization and Amputation Risk in **Type 2 Diabetes** to be Studied
Background
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder associated with severe microvascular and macrovascular complications, including heart failure and lower extremity amputation. While newer antihyperglycemic agents like SGLT2 inhibitors have shown cardiovascular benefits, their real-world comparative effectiveness against other treatments on these specific outcomes, especially amputation risk, warrants further investigation. This study aims to fill this evidence gap by analyzing large claims databases.
Study Design
This new-user active-comparative database study will analyze national United States claims data to compare canagliflozin against alternative antihyperglycemic treatments. Participants will be defined as exposed from their first treatment start between April 1, 2013, and May 15, 2017, and followed throughout treatment, analogous to an intention-to-treat (ITT) design. The primary endpoints are hospitalization for heart failure and below-knee lower extremity amputation in T2DM patients.
Why It Matters
This real-world evidence study, once completed, will provide crucial insights into the comparative safety and effectiveness of canagliflozin versus other diabetes medications regarding heart failure and amputation risk. Understanding these real-world outcomes can inform clinical guidelines and prescribing practices for T2DM patients, particularly those with established cardiovascular disease. It will help clinicians weigh the benefits and risks of different treatment strategies beyond controlled trial settings, offering a broader perspective on long-term patient outcomes.
canagliflozin
type-2-diabetes
heart-failure
amputation
sglt2-inhibitor
cohort-study